Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465172 · ClinicalTrials.gov registry record · NA
GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer
A NA study, sponsored by Breast Cancer Trials, Australia and New Zealand.
- Not yet
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT07465172 is a NA study that has not yet begun recruiting, run by Breast Cancer Trials, Australia and New Zealand. The registered enrollment target is 150 participants.
The verdict
NCT07465172, a NA study, has not yet begun recruiting, sponsored by Breast Cancer Trials, Australia and New Zealand.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
GRADE is trying to find out if there is a link between a hormone called GDF-15 and the side effects that people can experience when taking T-DXd. GDF-15 can be measured in the blood. GDF-15 levels in the blood will go up when the body is stressed under certain conditions, including breast cancer. There is a link between high GDF-15 levels and the nausea and vomiting experienced with "morning sickness" in pregnancy. It has also been shown that GDF-15 levels will go up with the use of other types of chemotherapy that are known to cause nausea and vomiting. Side effects such as feeling sick (nausea), vomiting and weight loss are common with T-DXd. Sometimes, these can be so severe that treatment needs to be stopped early. The investigators can't predict who will get bad side effects and who will not. If the investigators can find out if there is a link between GDF-15 and the side effects of T-DXd, they can use this information in future clinical trials.
Interventions
- OTHER Blood collection for GDF-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465172
The ClinicalTrials.gov registry entry for NCT07465172 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Breast Cancer Trials, Australia and New Zealand, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood collection for GDF-15 is the first listed.
NCT07465172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07465172 about?
NCT07465172 is a clinical study titled "GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer". GRADE is trying to find out if there is a link between a hormone called GDF-15 and the side effects that people can experience when taking T-DXd. GDF-15 can be measured in the blood. GDF-15 levels in the blood will go up when the body is stressed under certain conditions, including breast cancer. T...
What is the current status of trial NCT07465172?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-03. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07465172?
The interventions under investigation include: Blood collection for GDF-15 (OTHER).
Who is sponsoring clinical trial NCT07465172?
This trial is sponsored by Breast Cancer Trials, Australia and New Zealand, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.